Endogenous Recovery of Fasting C‐Peptide Decreases Progression of Sudomotor Small‐Fibre Dysfunction in Adults With Diabetes: A Real‐World Cohort Study
Diabetes/Metabolism Research and Reviews · 2026-05 · 42 (4)
DOI: 10.1002/dmrr.70173 ↗At a glance
Kohortenstudie in Diabetes/Metabolism Research and Reviews, published online on 2026-04-28. Written by Qingyun Cai and 5 co-authors. Institution: Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Beijing, China. Major MEDLINE topics: C-Peptide, Diabetic Neuropathies, Fasting, Diabetes Mellitus, Type 2. 27 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Noncommunicable Chronic Diseases-National Science and Technology Major Project of china.
Topics: Diabetes mellitus
Abstract (original language)
Aims
To determine whether recovery of fasting C‐peptide (ΔFCP) reduces deterioration in sudomotor small‐fibre function, whether a threshold exists, and whether associations are complication‐specific.
Methods
Retrospective real‐world cohort of 288 hospitalised adults with diabetes with repeated fasting C‐peptide and Sudoscan electrochemical skin conductance (ESC). Deterioration in sudomotor small‐fibre function was defined as worsening foot ESC. Large‐fibre neuropathy (LFN) and diabetic kidney disease (DKD) progression were assessed by nerve conduction and kidney outcomes. Cox models, restricted cubic splines, maximally selected rank statistics, and subgroup/landmark/sensitivity analyses were performed.
Results
Over a median 2.2 years, higher ΔFCP was independently associated with lower risk of deterioration in sudomotor small‐fibre function, but not with LFN or DKD progression. Highest versus lowest ΔFCP tertile: adjusted HR 0.31 (95% CI 0.14–0.69; p < 0.001). An optimal ΔFCP cutoff of 126.8 pmol/L was identified; ΔFCP ≥ 126.8 pmol/L was associated with a 66% lower risk of sudomotor deterioration (HR 0.34, 95% CI 0.17–0.69; p < 0.001), remaining robust in landmark and sensitivity analyses. Baseline C‐peptide mediated little of the association.
Conclusions
Endogenous fasting C‐peptide recovery is linked to a clinically meaningful, threshold‐dependent reduction in the progression of sudomotor small‐fibre dysfunction, supporting β ‐cell preservation/recovery as targets in early diabetic neuropathy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Beijing, China.
- Peking Union Medical College Graduate School, Chinese Academy of Medical Sciences, Beijing, China.
ORCID profiles: Qingyun Cai, Lixin Guo, Qi Pan
Funding
- Noncommunicable Chronic Diseases-National Science and Technology Major Project of china
Cite
APA
Cai, Q., Xie, T., Gong, H., Zhang, W., Guo, L., & Pan, Q. (2026). Endogenous Recovery of Fasting C‐Peptide Decreases Progression of Sudomotor Small‐Fibre Dysfunction in Adults With Diabetes: A Real‐World Cohort Study. Diabetes/Metabolism Research and Reviews, 42(4). https://doi.org/10.1002/dmrr.70173
Vancouver
Cai Q, Xie T, Gong H, Zhang W, Guo L, Pan Q. Endogenous Recovery of Fasting C‐Peptide Decreases Progression of Sudomotor Small‐Fibre Dysfunction in Adults With Diabetes: A Real‐World Cohort Study. Diabetes/Metabolism Research and Reviews. 2026;42(4). doi:10.1002/dmrr.70173
BibTeX
@article{Cai2026,
author = {Cai, Qingyun and Xie, Ting and Gong, Hongjian and Zhang, Wenjie and Guo, Lixin and Pan, Qi},
title = {Endogenous Recovery of Fasting C‐Peptide Decreases Progression of Sudomotor Small‐Fibre Dysfunction in Adults With Diabetes: A Real‐World Cohort Study},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2026},
volume = {42},
number = {4},
doi = {10.1002/dmrr.70173}
}
EUVIMED